Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 27
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/1/2007
 
First Published:
4/1/1994
1.
Phase III Randomized Study of Radiotherapy With or Without Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Versus ABVD Only in Patients With Stage I-IIA Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
16 and over
Other
CAN-NCIC-HD6
E-JHD06, NCI-V94-0427, NCT00002561, HD6, JHD06
2.
Phase III Pilot Study of Alternating Courses of MOPP and ABDV plus Radiotherapy with or without Levamisole for Advanced Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
no age specified
MSKCC-75104
Last Modified:
9/28/2006
 
First Published:
8/1/1998
3.
Phase III Randomized Study of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Versus Doxorubicin, Vinblastine, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone (Stanford V) With or Without Radiotherapy in Patients With Locally Extensive or Advanced Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
16 and over
NCI
ECOG-2496
CAN-NCIC-HD7, CALGB-59905, SWOG-E2496, E2496, NCT00003389, HD7
Last Modified:
5/21/2007
 
First Published:
9/1/1998
4.
Phase III Randomized Study of a Four-Drug Anthracycline-Based Regimen or a Seven-Drug Hybrid or Eight-Drug Alternating Regimen in Patients With Advanced Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
MRC-UKLG-LY09
EU-98020, NCT00003421
Last Modified:
6/12/2007
 
First Published:
4/1/2000
5.
Phase III Randomized Study of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With or Without Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in Patients With Stage III or IV Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
15 to 65
NCI
SWOG-S9901
CLB-59802, E-S9901, NCT00005090, S9901
Last Modified:
12/1/1997
6.
Phase III Extended vs Involved Field Radiotherapy with or without MOPP Chemotherapy for Childhood Hodgkin's Disease (Summary Last Modified 12/97 km)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
under 18
NCI
CCG-541
CLB-7691, POG-7660
7.
Phase III Radiotherapy plus MOPP (NM/VCR/PCB/PRED) and ABVD (ADR/BLEO/VBL/DTIC) for Stage I/II Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
MDA-RT-8001
Last Modified:
1/25/2008
8.
Phase III Study of MOPP (NM/VCR/PCB/PRED) vs ABVD (ADR/BLEO/VBL/DTIC) vs Alternating MOPP and ABVD for Stage III/IV Hodgkin's Disease and for Selected Patients with Stage I/II Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
16 and over
NCI
CLB-8251
CALGB-8251
9.
Phase III Radiotherapy Alone or in Combination with MOPP (NM/VCR/PCB/PRED) or MLMOPP (MOPP plus MTX/CF) for Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
UCCRC-2121B
NCI-V83-0124
10.
Phase III MOPP (NM/VCR/PCB/PRED) plus Radiotherapy and ABVD (ADR/BLEO/VBL/DTIC), CVPP (CTX/VBL/PCB/PRED), or AB-DIC (ADR/BLEO/DTIC/CCNU/PRED) Salvage Therapy for Stage III Hodgkin's Disease in Adults
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
MDA-IM-8007
NCI-V86-0049
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute